Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$2.08 - $3.6 $111,467 - $192,924
-53,590 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$3.36 - $10.56 $6,296 - $19,789
1,874 Added 3.62%
53,590 $188,000
Q1 2021

May 03, 2021

SELL
$9.26 - $14.36 $16,871 - $26,163
-1,822 Reduced 3.4%
51,716 $510,000
Q4 2020

Feb 12, 2021

BUY
$9.84 - $14.26 $39,438 - $57,154
4,008 Added 8.09%
53,538 $580,000
Q3 2020

Nov 09, 2020

BUY
$10.3 - $21.64 $61,439 - $129,082
5,965 Added 13.69%
49,530 $510,000
Q2 2020

Aug 10, 2020

BUY
$8.53 - $25.64 $37,412 - $112,457
4,386 Added 11.19%
43,565 $901,000
Q1 2020

May 15, 2020

BUY
$7.98 - $16.32 $48,829 - $99,862
6,119 Added 18.51%
39,179 $383,000
Q4 2019

Feb 14, 2020

SELL
$5.12 - $12.22 $4,853 - $11,584
-948 Reduced 2.79%
33,060 $381,000
Q3 2019

Nov 12, 2019

BUY
$5.24 - $15.89 $2,751 - $8,342
525 Added 1.57%
34,008 $185,000
Q2 2019

Aug 14, 2019

SELL
$5.1 - $11.89 $23,322 - $54,372
-4,573 Reduced 12.02%
33,483 $398,000
Q1 2019

May 13, 2019

BUY
$3.03 - $6.02 $5,802 - $11,528
1,915 Added 5.3%
38,056 $199,000
Q4 2018

Feb 14, 2019

SELL
$2.87 - $5.92 $3,426 - $7,068
-1,194 Reduced 3.2%
36,141 $114,000
Q3 2018

Nov 14, 2018

SELL
$4.5 - $7.6 $28,080 - $47,424
-6,240 Reduced 14.32%
37,335 $226,000
Q2 2018

Aug 14, 2018

BUY
$5.3 - $6.9 $224,370 - $292,104
42,334 Added 3411.28%
43,575 $232,000
Q1 2018

May 15, 2018

SELL
$3.65 - $7.95 $4,595 - $10,009
-1,259 Reduced 50.36%
1,241 $7,000
Q4 2017

Feb 08, 2018

BUY
$2.85 - $3.95 $5,970 - $8,275
2,095 Added 517.28%
2,500 $9,000
Q3 2017

Nov 14, 2017

BUY
$2.45 - $3.65 $992 - $1,478
405
405 $1,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $720M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.